Afya (NasdaqGS:AFYA) is back in focus after recent trading put its month and past 3 months performance under scrutiny, prompting investors to reassess what the current $13.95 share price implies.

Recent trading has been soft, with the 7 day share price return down 3.39% and the year to date share price return down 6.69%. The 3 year total shareholder return of 11.37% contrasts with a 5 year total shareholder return decline of 45.10%, which points to mixed momentum around Afya stock.

If Afya's recent moves have you reassessing your watchlist, it could be a useful moment to scan for other education related or knowledge focused businesses through our 20 top founder-led companies

With Afya stock down over the past year but still showing a positive 3 year total return, the real question is whether the current $13.95 price reflects a discount or whether the market is already pricing in future growth potential.

Most Popular Narrative: 19.2% Undervalued

Afya's most followed valuation narrative puts fair value at $17.25, comfortably above the recent $13.95 close, which raises clear questions about what is baked into the current price.

The company expects continued strong demand for medical education in Brazil, fueled by the country's persistent shortage of physicians, expanding aging population, and greater healthcare access, supporting both rising student intake and stable or rebounding tuition pricing, which drives higher revenues over time.

Read the complete narrative. Read the complete narrative.

Want to see why this narrative supports a higher valuation for Afya stock? It rests on steady revenue expansion, firmer margins, and a future earnings profile that uses a lower P/E than many peers. The real interest lies in how those moving parts combine under a single discount rate to arrive at that $17.25 figure.

Result: Fair Value of $17.25 (UNDERVALUED)

However, this Afya narrative could be challenged if higher Brazilian tax rates squeeze net margins, or if softer engagement in Medical Practice Solutions curbs higher margin digital revenue.

Next Steps

Given this mix of optimism and concern around Afya, it makes sense to look at the underlying data yourself and form a clear view quickly. To see how the balance between potential upside and flagged issues stacks up in one place, review the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Afya stock?

If Afya has sharpened your interest in opportunities, do not stop here. Use the Simply Wall Street Screener to uncover more focused, data driven stock ideas.

• Target steadier cash generators by reviewing companies in the 9 dividend fortresses that may suit an income focused approach.
• Hunt for potential value by scanning the screener containing 20 high quality undiscovered gems that highlight businesses the market may be overlooking.
• Prioritize resilience by checking the 68 resilient stocks with low risk scores to see which companies score well on Simply Wall Street's risk measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.